Mirum Pharmaceuticals, Inc.
MIRMNasdaq
$118.86
↑ +1.3%Jul 17 close · end-of-day
Price
1Y↑ +125.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.0B
Enterprise Value
$6.6B
P/E
—
P/S
12.3
P/B
28.8
EV/EBITDA
—
PEG
—
FCF Yield
-2.5%
Dividend Yield
—
Revenue (TTM)
$569.6M
Net Income (TTM)
-$798.8M
Free Cash Flow (TTM)
-$172.6M
Gross Margin
—
Operating Margin
-139.8%
Net Margin
-140.2%
ROE
-329.4%
ROIC
—
Debt / Equity
—
Net Cash
$386.3M
Return 1Y
+125.4%
Company profile
Mirum Pharmaceuticals, Inc. focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease.
- CEO
- Christopher Peetz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Headquarters
- California
- Website
- mirumpharma.com
Management & directors
- Bjerkholt EricCHIEF FINANCIAL OFFICER
- Peetz ChristopherCHIEF EXECUTIVE OFFICER
- Howe JolandaSVP, GLOBAL CONTROLLER
- Radovich PeterPRESIDENT AND COO
- Quan JoanneCHIEF MEDICAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
MIRM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$159.9M↑ +43.3%
Diluted EPS-$13.43↑ +4376.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$104.3M | -$173.4M | -$131.2M | -$109.2M | -$87.6M | -$22.1M |
| Net income | -$103.3M | -$84.0M | -$135.7M | -$163.4M | -$87.9M | -$23.4M |
| Diluted EPS | — | -$2.77 | -$4.02 | -$4.00 | -$1.85 | -$0.47 |
| Operating cash flow | -$89.1M | -$132.8M | -$120.1M | -$70.9M | $10.3M | $55.8M |
| Free cash flow | -$89.3M | -$132.8M | -$120.4M | -$71.1M | $9.3M | $54.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Net margin | — | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $77.9M | $90.4M | $99.4M | $111.6M | $127.8M | $133.0M | $148.9M | $159.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.2M | -$12.7M | -$24.2M | -$15.2M | -$5.0M | $2.6M | -$4.6M | -$789.5M |
| Net income | -$24.6M | -$14.2M | -$23.8M | -$14.7M | -$5.9M | $2.9M | -$5.7M | -$790.2M |
| Diluted EPS | -$0.52 | -$0.30 | -$0.49 | -$0.30 | -$0.12 | $0.05 | -$0.10 | -$13.43 |
| Operating cash flow | -$3.8M | $4.0M | -$5.1M | -$2.0M | $12.0M | $39.7M | $6.1M | -$228.8M |
| Free cash flow | -$4.6M | $3.8M | -$5.1M | -$2.0M | $11.9M | $39.5M | $5.5M | -$229.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -31.1% | -14.0% | -24.4% | -13.6% | -3.9% | 2.0% | -3.1% | -493.8% |
| Net margin | -31.6% | -15.8% | -23.9% | -13.2% | -4.6% | 2.2% | -3.8% | -494.2% |
Company news
Jul 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 12,134 | $121.65 | $1.5M | filing |
| 2026-07-06 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 4,181 | $122.34 | $511,503.54 | filing |
| 2026-07-06 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Sale | 3,124 | $121.67 | $380,097.08 | filing |
| 2026-07-06 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 1,975 | $123.74 | $244,386.50 | filing |
| 2026-07-06 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 1,710 | $124.79 | $213,390.90 | filing |
| 2026-07-06 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Sale | 1,048 | $122.43 | $128,306.64 | filing |
| 2026-07-06 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Sale | 528 | $123.84 | $65,387.52 | filing |
| 2026-07-06 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Option exercise | 20,000 | $2.94 | $58,720.00 | filing |
| 2026-07-06 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Sale | 300 | $124.94 | $37,482.00 | filing |
| 2026-07-01 | Howe Jolanda· SVP, GLOBAL CONTROLLER | Sale | 2,721 | $120.00 | $326,520.00 | filing |
| 2026-06-17 | Howe Jolanda· SVP, GLOBAL CONTROLLER | Sale | 2,594 | $101.95 | $264,458.30 | filing |
| 2026-06-09 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Option exercise | 2,393 | $26.49 | $63,390.57 | filing |
| 2026-06-08 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Sale | 2,258 | $92.84 | $209,632.72 | filing |
| 2026-06-08 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Sale | 1,567 | $95.12 | $149,053.04 | filing |
| 2026-06-08 | BJERKHOLT ERIC· CHIEF FINANCIAL OFFICER | Sale | 1,175 | $93.95 | $110,391.25 | filing |
| 2026-06-05 | Radovich Peter· PRESIDENT AND COO | Option exercise | 16,988 | $19.19 | $325,999.72 | filing |
| 2026-06-01 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 16,595 | $95.34 | $1.6M | filing |
| 2026-06-01 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 6,926 | $96.15 | $665,934.90 | filing |
| 2026-06-01 | Ramasastry Saira | Sale | 3,977 | $100.00 | $397,700.00 | filing |
| 2026-06-01 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 2,602 | $94.64 | $246,253.28 | filing |
| 2026-06-01 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 1,973 | $97.56 | $192,485.88 | filing |
| 2026-06-01 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 1,021 | $98.20 | $100,262.20 | filing |
| 2026-06-01 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Option exercise | 30,000 | $2.94 | $88,080.00 | filing |
| 2026-06-01 | Peetz Christopher· CHIEF EXECUTIVE OFFICER | Sale | 883 | $99.66 | $87,999.78 | filing |
| 2026-05-29 | Walbert Timothy P | Option exercise | 3,977 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.